HRP20100434T1 - Postupci liječenja zaraze virusom hiv - Google Patents
Postupci liječenja zaraze virusom hiv Download PDFInfo
- Publication number
- HRP20100434T1 HRP20100434T1 HR20100434T HRP20100434T HRP20100434T1 HR P20100434 T1 HRP20100434 T1 HR P20100434T1 HR 20100434 T HR20100434 T HR 20100434T HR P20100434 T HRP20100434 T HR P20100434T HR P20100434 T1 HRP20100434 T1 HR P20100434T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- solvate
- acceptable salt
- agent
- treatment
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title claims abstract 11
- 208000037357 HIV infectious disease Diseases 0.000 title claims abstract 10
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title claims abstract 10
- 150000003839 salts Chemical class 0.000 claims abstract 17
- 239000012453 solvate Substances 0.000 claims abstract 17
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims abstract 14
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims abstract 7
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims abstract 7
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims abstract 7
- 108010032976 Enfuvirtide Proteins 0.000 claims abstract 7
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims abstract 7
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims abstract 7
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims abstract 7
- 229960005319 delavirdine Drugs 0.000 claims abstract 7
- 229960002656 didanosine Drugs 0.000 claims abstract 7
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims abstract 7
- 229960003804 efavirenz Drugs 0.000 claims abstract 7
- 229960000366 emtricitabine Drugs 0.000 claims abstract 7
- 229960002062 enfuvirtide Drugs 0.000 claims abstract 7
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 claims abstract 7
- 229960002169 plerixafor Drugs 0.000 claims abstract 7
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 claims abstract 7
- 229960000311 ritonavir Drugs 0.000 claims abstract 7
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims abstract 7
- 229960001852 saquinavir Drugs 0.000 claims abstract 7
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims abstract 7
- 229960001203 stavudine Drugs 0.000 claims abstract 7
- 229960004556 tenofovir Drugs 0.000 claims abstract 7
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims abstract 7
- 229960000523 zalcitabine Drugs 0.000 claims abstract 7
- 208000030507 AIDS Diseases 0.000 claims abstract 6
- 239000003814 drug Substances 0.000 claims abstract 3
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 239000003795 chemical substances by application Substances 0.000 claims 10
- GACIOSIZKMLELV-POHAHGRESA-N (z)-4-[(4-fluorophenyl)methyl-methoxyamino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(/O)=C/C(=O)N(OC)CC1=CC=C(F)C=C1 GACIOSIZKMLELV-POHAHGRESA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- QRPZBKAMSFHVRW-UHFFFAOYSA-N 1-(4-benzoylpiperazin-1-yl)-2-[4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)-1h-pyrrolo[2,3-c]pyridin-3-yl]ethane-1,2-dione Chemical compound C1=2NC=C(C(=O)C(=O)N3CCN(CC3)C(=O)C=3C=CC=CC=3)C=2C(OC)=CN=C1N1C=NC(C)=N1 QRPZBKAMSFHVRW-UHFFFAOYSA-N 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- -1 3-methyl-1H-1,2,4-triazol-1-yl Chemical group 0.000 abstract 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Uporaba 1-benzoil-4-[2-[4-metoksi-7-(3-metil-1H-1,2,4-triazol-1-il)-1H pirolo [2,3-c] piridin-3-il]-1,2-dioksoetil]-piperazina, ili njegove farmaceutski prihvatljive soli ili solvata, naznačena time što se radi o uporabi za proizvodnju lijeka za liječenje zaraze virusom HIV kod ljudskog bolesnika, s barem još jednim drugim sredstvom za liječenje AIDS-a ili zaraze virusom HIV, izabranim iz skupine koja obuhvaća zalcitabin, emtricitabin, didanozin, tenofovir, stavudin, efavirenz, delavirdin, ritonavir, sakvinavir, enfuvirtid, AMD-3100 i 3-[(4-fluorobenzil)metoksikarbamoil]-2-hidroksiakrilnu kiselinu, ili njihovu farmaceutski prihvatljivu sol ili solvat. Patent sadrži još 9 patentnih zahtjeva.
Claims (10)
1. Uporaba 1-benzoil-4-[2-[4-metoksi-7-(3-metil-1H-1,2,4-triazol-1-il)-1H pirolo [2,3-c] piridin-3-il]-1,2-dioksoetil]-piperazina, ili njegove farmaceutski prihvatljive soli ili solvata, naznačena time što se radi o uporabi za proizvodnju lijeka za liječenje zaraze virusom HIV kod ljudskog bolesnika, s barem još jednim drugim sredstvom za liječenje AIDS-a ili zaraze virusom HIV, izabranim iz skupine koja obuhvaća zalcitabin, emtricitabin, didanozin, tenofovir, stavudin, efavirenz, delavirdin, ritonavir, sakvinavir, enfuvirtid, AMD-3100 i 3-[(4-fluorobenzil)metoksikarbamoil]-2-hidroksiakrilnu kiselinu, ili njihovu farmaceutski prihvatljivu sol ili solvat.
2. Uporaba 1-benzoil-4-[2-[4-metoksi-7-(3-metil-1H-1,2,4-triazol-1-il)-1H pirolo [2,3-c] piridin-3-il]-1,2-dioksoetil]-piperazina, ili njegove farmaceutski prihvatljive soli ili solvata, naznačena time što se radi o uporabi za proizvodnju lijeka koji se koristi u kombinaciji, ali odvojeno, s barem još jednim drugim sredstvom za liječenje AIDS-a ili zaraze virusom HIV, izabranim iz skupine koja obuhvaća zalcitabin, emtricitabin, didanozin, tenofovir, stavudin, efavirenz, delavirdin, ritonavir, sakvinavir, enfuvirtid, AMD-3100 i 3-[(4-fluorobenzil)metoksikarbamoil]-2-hidroksiakrilnu kiselinu, ili njihovu farmaceutski prihvatljivu sol ili solvat, za liječenje zaraze virusom HIV kod ljudskog bolesnika.
3. 1-benzoil-4-[2-[4-metoksi-7-(3-metil-1H-1,2,4-triazol-1-il)-1H-pirolo[2,3-c]piridin-3-il]-1,2-dioksoetil]-piperazin, ili njegova farmaceutski prihvatljiva sol ili solvat, i barem još jedno drugo sredstvo za liječenje AIDS-a ili zaraze virusom HIV, izabrano iz skupine koja obuhvaća zalcitabin, emtricitabin, didanozin, tenofovir, stavudin, efavirenz, delavirdin, ritonavir, sakvinavir, enfuvirtid, AMD-3100 i 3-[(4-fluorobenzil)metoksikarbamoil]-2-hidroksiakrilnu kiselinu, ili njihovu farmaceutski prihvatljivu sol ili solvat, naznačeni time što su za uporabu u liječenju zaraze virusom HIV kod ljudskog bolesnika.
4. 1-benzoil-4-[2-[4-metoksi-7-(3-metil-1H-1,2,4-triazol-1-il)-1H-pirolo[2,3-c]piridin-3-il]-1,2-dioksoetil]-piperazin, ili njegova farmaceutski prihvatljiva sol ili solvat, za uporabu u kombinaciji, ali odvojeno, s barem još jednim drugim sredstvom za liječenje AIDS-a ili zaraze virusom HIV, izabranim iz skupine koja obuhvaća zalcitabin, emtricitabin, didanozin, tenofovir, stavudin, efavirenz, delavirdin, ritonavir, sakvinavir, enfuvirtid, AMD-3100 i 3-[(4-fluorobenzil)metoksikarbamoil]-2-hidroksiakrilnu kiselinu, ili njihovu farmaceutski prihvatljivu sol ili solvat, naznačeno time što se radi o uporabi za liječenje zaraze virusom HIV kod ljudskog bolesnika.
5. Farmaceutska smjesa, naznačena time što sadrži terapijski učinkovitu količinu 1-benzoil-4-[2-[4-metoksi-7-(3-metil-1H-1,2,4-triazol-1-il)-1H-pirolo[2,3-c]piridin-3-il]-1,2-dioksoetil]-piperazina, ili njegove farmaceutski prihvatljive soli ili solvata, s još barem jednim drugim sredstvom za liječenje AIDS-a ili zaraze virusom HIV, izabranim iz skupine koja obuhvaća zalcitabin, emtricitabin, didanozin, tenofovir, stavudin, efavirenz, delavirdin, ritonavir, sakvinavir, enfuvirtid, AMD-3100 i 3-[(4-fluorobenzil)metoksikarbamoil]-2-hidroksiakrilnu kiselinu, ili njihovu farmaceutski prihvatljivu sol ili solvat, i farmaceutski prihvatljiv nosač.
6. Uporaba prema zahtjevu 1 ili 2, spoj prema zahtjevu 4 ili smjesa prema zahtjevu 3 ili 5, naznačeno time što se sredstvo izabire između zalcitabina, emtricitabina, didanozina, tenofovira i stavudina, ili njihove farmaceutski prihvatljive soli ili solvata.
7. Uporaba prema zahtjevu 1 ili 2, spoj prema zahtjevu 4 ili smjesa prema zahtjevu 3 ili 5, naznačeno time što se sredstvo izabire između efavirenza i delavirdina, ili njihove farmaceutski prihvatljive soli ili solvata.
8. Uporaba prema zahtjevu 1 ili 2, spoj prema zahtjevu 4 ili smjesa prema zahtjevu 3 ili 5, naznačeno time što se sredstvo izabire između ritonavira i sakvinavira, ili njihove farmaceutski prihvatljive soli ili solvata.
9. Uporaba prema zahtjevu 1 ili 2, spoj prema zahtjevu 4 ili smjesa prema zahtjevu 3 ili 5, naznačeno time što se sredstvo izabire između enfuvirtida i AMD-3100, ili njihove farmaceutski prihvatljive soli ili solvata.
10. Uporaba prema zahtjevu 1 ili 2, spoj prema zahtjevu 4 ili smjesa prema zahtjevu 3 ili 5, naznačeno time što se sredstvo izabire između 3-[(4-fluorobenzil)metoksikarbamoil]-2-hidroksiakrilne kiseline, ili njezine farmaceutski prihvatljive soli ili solvata.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55576704P | 2004-03-24 | 2004-03-24 | |
| PCT/US2005/006277 WO2005102392A2 (en) | 2004-03-24 | 2005-03-01 | Combinations for treating hiv infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100434T1 true HRP20100434T1 (hr) | 2010-09-30 |
Family
ID=34961940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100434T HRP20100434T1 (hr) | 2004-03-24 | 2010-08-03 | Postupci liječenja zaraze virusom hiv |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US7776863B2 (hr) |
| EP (1) | EP1732604B1 (hr) |
| JP (1) | JP4847441B2 (hr) |
| KR (1) | KR101158140B1 (hr) |
| CN (1) | CN1956720B (hr) |
| AR (1) | AR048333A1 (hr) |
| AT (1) | ATE474602T1 (hr) |
| AU (1) | AU2005235116B2 (hr) |
| BR (1) | BRPI0509140A (hr) |
| CA (1) | CA2561146C (hr) |
| CY (1) | CY1111613T1 (hr) |
| DE (1) | DE602005022420D1 (hr) |
| DK (1) | DK1732604T3 (hr) |
| ES (1) | ES2347801T3 (hr) |
| GE (1) | GEP20104925B (hr) |
| HK (1) | HK1096540A1 (hr) |
| HR (1) | HRP20100434T1 (hr) |
| IL (1) | IL178141A (hr) |
| IN (1) | IN2012DN06436A (hr) |
| MY (1) | MY144318A (hr) |
| NO (1) | NO337116B1 (hr) |
| NZ (1) | NZ549778A (hr) |
| PE (1) | PE20060148A1 (hr) |
| PL (1) | PL1732604T3 (hr) |
| PT (1) | PT1732604E (hr) |
| RU (1) | RU2367439C2 (hr) |
| SI (1) | SI1732604T1 (hr) |
| TW (1) | TWI347184B (hr) |
| UA (1) | UA88463C2 (hr) |
| WO (1) | WO2005102392A2 (hr) |
| ZA (1) | ZA200607959B (hr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040110785A1 (en) * | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| US20060100432A1 (en) * | 2004-11-09 | 2006-05-11 | Matiskella John D | Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| US20060100209A1 (en) * | 2004-11-09 | 2006-05-11 | Chong-Hui Gu | Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| PT1942108E (pt) | 2005-10-28 | 2013-10-24 | Ono Pharmaceutical Co | Composto com um grupo básico e a sua utilização |
| ES2407115T3 (es) | 2005-11-18 | 2013-06-11 | Ono Pharmaceutical Co., Ltd. | Compuesto que contiene un grupo básico y uso del mismo |
| US7851476B2 (en) * | 2005-12-14 | 2010-12-14 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine |
| US7501419B2 (en) * | 2006-04-25 | 2009-03-10 | Bristol-Myers Squibb Company | 4-Squarylpiperazine derivatives as antiviral agents |
| US7807671B2 (en) | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
| US7504399B2 (en) | 2006-06-08 | 2009-03-17 | Bristol-Meyers Squibb Company | Piperazine enamines as antiviral agents |
| US7572810B2 (en) * | 2006-06-08 | 2009-08-11 | Bristol-Myers Squibb Company | Alkene piperidine derivatives as antiviral agents |
| US7960406B2 (en) | 2008-06-25 | 2011-06-14 | Bristol-Myers Squibb Company | Diketo substituted pyrrolo[2,3-c] pyridines |
| CN102076686B (zh) * | 2008-06-25 | 2013-03-06 | 百时美施贵宝公司 | 作为hiv附着抑制剂的二酮哌啶衍生物 |
| US20110290821A1 (en) * | 2010-05-28 | 2011-12-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-viral compositions and methods for administration |
| US8450361B2 (en) | 2010-08-06 | 2013-05-28 | Bristol-Myers Squibb Company | Substituted indole and azaindole oxoacetyl piperazinamide derivatives |
| ES2585396T3 (es) | 2010-12-02 | 2016-10-05 | VIIV Healthcare UK (No.5) Limited | Alquilamidas como inhibidores de la unión del VIH |
| US8436168B2 (en) | 2011-01-31 | 2013-05-07 | Bristol-Myers Squibb Company | Methods of making HIV attachment inhibitor prodrug compound and intermediates |
| US8685982B2 (en) | 2011-04-12 | 2014-04-01 | Bristol-Myers Squibb Company | Thioamide, amidoxime and amidrazone derivatives as HIV attachment inhibitors |
| ES2616268T3 (es) | 2011-08-29 | 2017-06-12 | VIIV Healthcare UK (No.5) Limited | Derivados condensados de diamina bicíclica como inhibidores de la unión de VIH |
| EP2751118B1 (en) | 2011-08-29 | 2016-10-12 | Bristol-Myers Squibb Company | Spiro bicyclic diamine derivatives as hiv attachment inhibitors |
| US9193725B2 (en) | 2012-03-14 | 2015-11-24 | Bristol-Meyers Squibb Company | Cyclic hydrazine derivatives as HIV attachment inhibitors |
| EP2895472B1 (en) | 2012-08-09 | 2016-11-23 | VIIV Healthcare UK (No.5) Limited | Tricyclic alkene derivatives as HIV attachment inhibitors |
| EP2895471B1 (en) | 2012-08-09 | 2016-11-23 | VIIV Healthcare UK (No.5) Limited | Piperidine amide derivatives as hiv attachment inhibitors |
| US9586957B2 (en) * | 2013-03-27 | 2017-03-07 | VIIV Healthcare UK (No.5) Limited | 2-keto amide derivatives as HIV attachment inhibitors |
| CA2988650A1 (en) | 2015-06-23 | 2016-12-29 | Cytodyn Inc. | Inhibition of ccl5 ligand binding to ccr5 receptor and alteration of ccr5/ccl5 axis signaling in inflammation, cancer, autoimmune, and other conditions |
| WO2023172635A1 (en) * | 2022-03-08 | 2023-09-14 | Emory University | Predictive model for variants associated with drug resistance and theranostic applications thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1068219B1 (en) * | 1998-03-02 | 2006-12-20 | The University of North Carolina at Chapel Hill | Acylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| US6476034B2 (en) | 2000-02-22 | 2002-11-05 | Bristol-Myers Squibb Company | Antiviral azaindole derivatives |
| US20040110785A1 (en) * | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US20030207910A1 (en) * | 2001-02-02 | 2003-11-06 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| CA2469592C (en) * | 2001-12-12 | 2005-08-23 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| RU2325387C2 (ru) * | 2001-12-21 | 2008-05-27 | Анормед Инк. | Гетероциклические соединения с повышенной эффективностью, связывающиеся с рецептором хемокина |
-
2005
- 2005-02-24 US US11/064,683 patent/US7776863B2/en active Active
- 2005-03-01 KR KR1020067019595A patent/KR101158140B1/ko active IP Right Grant
- 2005-03-01 EP EP05723932A patent/EP1732604B1/en active Active
- 2005-03-01 GE GEAP20059667A patent/GEP20104925B/en unknown
- 2005-03-01 NZ NZ549778A patent/NZ549778A/en unknown
- 2005-03-01 SI SI200531100T patent/SI1732604T1/sl unknown
- 2005-03-01 DK DK05723932.9T patent/DK1732604T3/da active
- 2005-03-01 DE DE602005022420T patent/DE602005022420D1/de active Active
- 2005-03-01 PT PT05723932T patent/PT1732604E/pt unknown
- 2005-03-01 PL PL05723932T patent/PL1732604T3/pl unknown
- 2005-03-01 UA UAA200611163A patent/UA88463C2/ru unknown
- 2005-03-01 ES ES05723932T patent/ES2347801T3/es active Active
- 2005-03-01 IN IN6436DEN2012 patent/IN2012DN06436A/en unknown
- 2005-03-01 BR BRPI0509140-3A patent/BRPI0509140A/pt not_active Application Discontinuation
- 2005-03-01 RU RU2006137555/14A patent/RU2367439C2/ru active
- 2005-03-01 AT AT05723932T patent/ATE474602T1/de active
- 2005-03-01 AU AU2005235116A patent/AU2005235116B2/en active Active
- 2005-03-01 JP JP2007504971A patent/JP4847441B2/ja active Active
- 2005-03-01 CN CN2005800160669A patent/CN1956720B/zh active Active
- 2005-03-01 CA CA2561146A patent/CA2561146C/en active Active
- 2005-03-01 WO PCT/US2005/006277 patent/WO2005102392A2/en active Application Filing
- 2005-03-17 MY MYPI20051136A patent/MY144318A/en unknown
- 2005-03-18 TW TW094108462A patent/TWI347184B/zh active
- 2005-03-23 AR ARP050101159A patent/AR048333A1/es active Pending
- 2005-03-28 PE PE2005000344A patent/PE20060148A1/es not_active Application Discontinuation
-
2006
- 2006-09-17 IL IL178141A patent/IL178141A/en active IP Right Review Request
- 2006-09-22 ZA ZA200607959A patent/ZA200607959B/en unknown
- 2006-10-06 NO NO20064547A patent/NO337116B1/no unknown
-
2007
- 2007-04-20 HK HK07104156.5A patent/HK1096540A1/xx unknown
-
2010
- 2010-08-03 HR HR20100434T patent/HRP20100434T1/hr unknown
- 2010-10-20 CY CY20101100937T patent/CY1111613T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100434T1 (hr) | Postupci liječenja zaraze virusom hiv | |
| BRPI0519471A2 (pt) | formulaÇço complexa de liberaÇço controlada para administraÇço oral de medicamentos para diabÉticos e mÉtodo para o seu preparo | |
| TN2018000335A1 (en) | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | |
| SI1509521T1 (sl) | 1H-imidazo(4,5-C)kinolinski derivati za zdravljenje od protein kinaze odvisnih bolezni | |
| AR048439A1 (es) | Composiciones farmaceuticas y metodos para tratar la infeccion por vih | |
| AR048324A1 (es) | Metodos para tratar infecciones por vih | |
| HRP20240082T1 (hr) | Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti | |
| JP2007530540A5 (hr) | ||
| TW200505924A (en) | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
| BR0209658A (pt) | Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina | |
| WO2006017505A3 (en) | Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases | |
| NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
| ATE453646T1 (de) | 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren | |
| IL198314A (en) | History of Quinuclidine of (hetero) Acrylic Cyclohepethecarboxylic Acid, Process of Preparation, Medicinal Preparations Containing Them and Use of Drug Preparation for Treatment | |
| WO2006072940A3 (en) | Controlled long acting release pharmaceutical preparation for use in the oral cavity | |
| MXPA06000302A (es) | Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden. | |
| NZ767295A (en) | Liquid inhalation formulation comprising rpl554 | |
| BRPI0413974A (pt) | combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| SI2889033T1 (en) | Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| WO2011151722A3 (en) | Methods and compositions for oral pharmaceutical therapy | |
| RU2006131553A (ru) | Комбинация(а) ингибитора топоизомеразы днк и (б) ингибитора iap | |
| UA102885C2 (ru) | Таблетка для орального введения, которая содержит тамсулозин и солифенацин | |
| BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase | |
| CN113727715A (zh) | 用伐昔洛韦和泛昔洛韦的组合治疗单纯疱疹 |